Company
PTC Therapeutics
PTC Therapeutics has 17 drugs tracked on RxWires: 2 approved, 4 in Phase 3, 2 in Phase 2/3, 7 in Phase 2, 1 in Phase 1/2, 1 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| EMFLAZA | Approved | |
| SILDENAFIL CITRATE | Approved | |
| Ataluren | Phase 3 | Cystic Fibrosis |
| Vatiquinone | Phase 3 | Inherited Mitochondrial Disease |
| PTC923 | Phase 3 | Phenylketonuria |
| Sepiapterin | Phase 3 | Phenylketonuria |
| PTC299 | Phase 2/3 | Pneumonia |
| Unesbulin | Phase 2/3 | Leiomyosarcoma |
| PTC124 | Phase 2 | Duchenne Muscular Dystrophy |
| Placebo | Phase 2 | Friedreich's Ataxia |
| AAV2-hAADC | Phase 2 | Aromatic Amino Acid Decarboxylase Deficiency |
| PTC844 | Phase 2 | Rheumatoid Arthritis |
| PTC857 | Phase 2 | Amyotrophic Lateral Sclerosis |
| Eladocagene Exuparvovec | Phase 2 | AADC Deficiency |
| EPI-743 | Phase 2 | Leigh Syndrome |
| VEGF inhibitor PTC299 | Phase 1/2 | Kaposi's Sarcoma |
| PTC596 | Phase 1 | Cancer |
Latest
- Unesbulin moved to Phase 2/3
- ptc therapeutics filed 8-K
- Exclusivity ends 2026-06-07 (application 208685)
- ptc therapeutics filed 8-K
- ptc therapeutics filed 8-K
Follow PTC Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.